Seoulin Bioscience Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	76,738	75,410	89,569	104,708	80,539	65,085
Other Revenue	-0	-0	-	-	-	-
Revenue	76,738	75,410	89,569	104,708	80,539	65,085
Revenue Growth (YoY)	-6.52%	-15.81%	-14.46%	30.01%	23.74%	19.62%
Cost of Revenue	58,854	56,450	69,699	80,417	59,469	48,569
Gross Profit	17,884	18,961	19,871	24,292	21,070	16,516
Selling, General & Admin	14,387	14,697	15,016	12,475	11,144	9,626
Research & Development	1,247	1,214	785.23	870.46	786.82	998.37
Amortization of Goodwill & Intangibles	81.81	92.26	112.83	163.33	459.01	371.5
Other Operating Expenses	496.65	483.24	441.22	396.47	382.27	335.09
Operating Expenses	17,531	18,008	17,376	15,094	13,619	12,046
Operating Income	353.32	952.67	2,495	9,198	7,451	4,471
Interest Expense	-379.31	-329.7	-2,482	-2,287	-224.55	-18.66
Interest & Investment Income	688.76	996.22	2,051	1,637	303.78	253.7
Earnings From Equity Investments	10.67	88.53	85.1	121.01	114.5	89.12
Currency Exchange Gain (Loss)	-50.36	10.01	-308.95	-63.7	-178.86	144.62
Other Non Operating Income (Expenses)	397.41	666.37	3,441	3,808	-397.15	724.33
EBT Excluding Unusual Items	1,020	2,384	5,280	12,413	7,069	5,664
Gain (Loss) on Sale of Investments	1,968	1,986	-4,966	2,011	160.11	118.2
Gain (Loss) on Sale of Assets	-0.32	-13.69	-31.42	-1.06	14,153	0.27
Asset Writedown	-152.6	-152.6	-	-393.03	-1,044	-
Other Unusual Items	-125.86	-648.11	-2,211	-	-	-
Pretax Income	2,710	3,556	-1,929	14,029	20,338	5,782
Income Tax Expense	43.05	415.34	394.29	3,464	4,459	981.4
Earnings From Continuing Operations	2,667	3,140	-2,323	10,565	15,879	4,801
Earnings From Discontinued Operations	-	-	-	29.47	-111.04	-
Net Income to Company	2,667	3,140	-2,323	10,595	15,768	4,801
Minority Interest in Earnings	-546.34	-226.34	2,206	-435.72	-178.88	91.64
Net Income	2,121	2,914	-117.55	10,159	15,589	4,893
Net Income to Common	2,121	2,914	-117.55	10,159	15,589	4,893
Net Income Growth	-	-	-	-34.84%	218.64%	-44.93%
Shares Outstanding (Basic)	9	9	9	9	9	9
Shares Outstanding (Diluted)	9	9	9	11	9	9
Shares Change (YoY)	4.78%	-0.50%	-19.46%	23.72%	-0.07%	-1.26%
EPS (Basic)	240.22	326.72	-13.11	1131.84	1733.06	543.54
EPS (Diluted)	222.54	326.51	-13.11	780.07	1732.89	543.39
EPS Growth	-	-	-	-54.98%	218.90%	-44.22%
Free Cash Flow	588.48	-4,660	-14.95	-4,817	7,984	3,283
Free Cash Flow Per Share	62.73	-522.49	-1.67	-432.86	887.61	364.74
Dividend Per Share	95.471	95.471	-	-	-	-
Gross Margin	23.31%	25.14%	22.18%	23.20%	26.16%	25.38%
Operating Margin	0.46%	1.26%	2.79%	8.78%	9.25%	6.87%
Profit Margin	2.76%	3.86%	-0.13%	9.70%	19.36%	7.52%
Free Cash Flow Margin	0.77%	-6.18%	-0.02%	-4.60%	9.91%	5.04%
EBITDA	1,573	2,318	3,781	10,215	9,381	6,455
EBITDA Margin	2.05%	3.07%	4.22%	9.75%	11.65%	9.92%
D&A For EBITDA	1,219	1,365	1,287	1,017	1,930	1,984
EBIT	353.32	952.67	2,495	9,198	7,451	4,471
EBIT Margin	0.46%	1.26%	2.79%	8.78%	9.25%	6.87%
Effective Tax Rate	1.59%	11.68%	-	24.69%	21.92%	16.97%
Advertising Expenses	-	357.36	227.45	119.05	141.61	183.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.